@prefix prodottidellaricerca: . @prefix istituto: . @prefix prodotto: . istituto:CDS015 prodottidellaricerca:prodotto prodotto:ID202617 . @prefix pubblicazioni: . @prefix unitaDiPersonaleInterno: . unitaDiPersonaleInterno:MATRICOLA657 pubblicazioni:autoreCNRDi prodotto:ID202617 . unitaDiPersonaleInterno:MATRICOLA8344 pubblicazioni:autoreCNRDi prodotto:ID202617 . unitaDiPersonaleInterno:MATRICOLA10688 pubblicazioni:autoreCNRDi prodotto:ID202617 . unitaDiPersonaleInterno:MATRICOLA14402 pubblicazioni:autoreCNRDi prodotto:ID202617 . @prefix modulo: . modulo:ID2562 prodottidellaricerca:prodotto prodotto:ID202617 . @prefix rdf: . @prefix retescientifica: . prodotto:ID202617 rdf:type retescientifica:ProdottoDellaRicerca , prodotto:TIPO1101 . @prefix rdfs: . prodotto:ID202617 rdfs:label "Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down's syndrome (Articolo in rivista)"@en . @prefix xsd: . prodotto:ID202617 pubblicazioni:anno "2013-01-01T00:00:00+01:00"^^xsd:gYear ; pubblicazioni:doi "10.1016/j.bbadis.2012.12.011"^^xsd:string . @prefix skos: . prodotto:ID202617 skos:altLabel "
Daniela Valenti, Domenico De Rasmo, Anna Signorile, Leonardo Rossi, Lidia de Bari, Iris Scala, Barbara Granese, Sergio Papa, Rosa Anna Vacca (2013)
Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down's syndrome
in Biochimica et biophysica acta. Molecular basis of disease
"^^rdf:HTML ; pubblicazioni:autori "Daniela Valenti, Domenico De Rasmo, Anna Signorile, Leonardo Rossi, Lidia de Bari, Iris Scala, Barbara Granese, Sergio Papa, Rosa Anna Vacca"^^xsd:string ; pubblicazioni:paginaInizio "542"^^xsd:string ; pubblicazioni:paginaFine "552"^^xsd:string ; pubblicazioni:numeroVolume "1832"^^xsd:string . @prefix ns11: . prodotto:ID202617 pubblicazioni:rivista ns11:ID275683 ; pubblicazioni:pagineTotali "10"^^xsd:string ; pubblicazioni:numeroFascicolo "4"^^xsd:string ; skos:note "ISI Web of Science (WOS)"^^xsd:string ; pubblicazioni:affiliazioni "Institute of Biomembranes and Bioenergetics, National Council of Research, Bari, Italy; \nDepartment of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Italy;\nLaboratory of Biology and Genetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy; \nDepartment of Pediatrics, Federico II University, Naples, Italy"^^xsd:string ; pubblicazioni:titolo "Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down's syndrome"^^xsd:string ; prodottidellaricerca:abstract "A critical role for mitochondrial dysfunction has been proposed in the pathogenesis of Down's syndrome (DS), a human multifactorial disorder caused by trisomy of chromosome 21, associated with mental retardation and early neurodegeneration. Previous studies from our group demonstrated in DS cells a decreased capacity of the mitochondrial ATP production system and overproduction of reactive oxygen species (ROS) in mitochondria. In this study we have tested the potential of epigallocatechin-3-gallate (EGCG) - a natural polyphenol component of green tea - to counteract the mitochondrial energy deficit found in DS cells. We found that EGCG, incubated with cultured lymphoblasts and fibroblasts from DS subjects, rescued mitochondrial complex I and ATP synthase catalytic activities, restored oxidative phosphorylation efficiency and counteracted oxidative stress. These effects were associated with EGCG-induced promotion of PKA activity, related to increased cellular levels of cAMP and PKA-dependent phosphorylation of the NDUFS4 subunit of complex I. In addition, EGCG strongly promoted mitochondrial biogenesis in DS cells, as associated with increase in Sirt1-dependent PGC-1? deacetylation, NRF-1 and T-FAM protein levels and mitochondrial DNA content. \nIn conclusion, this study shows that EGCG is a promoting effector of oxidative phosphorylation and mitochondrial biogenesis in DS cells, acting through modulation of the cAMP/PKA- and sirtuin-dependent pathways. EGCG treatment promises thus to be a therapeutic approach to counteract mitochondrial energy deficit and oxidative stress in DS."@en ; prodottidellaricerca:prodottoDi istituto:CDS015 , modulo:ID2562 ; pubblicazioni:autoreCNR unitaDiPersonaleInterno:MATRICOLA14402 , unitaDiPersonaleInterno:MATRICOLA10688 , unitaDiPersonaleInterno:MATRICOLA657 , unitaDiPersonaleInterno:MATRICOLA8344 . @prefix parolechiave: . prodotto:ID202617 parolechiave:insiemeDiParoleChiave . ns11:ID275683 pubblicazioni:rivistaDi prodotto:ID202617 . parolechiave:insiemeDiParoleChiaveDi prodotto:ID202617 .